On the afternoon of September 27, the Financing M&A Forum (hereinafter referred to as “Forum”) was successfully held on the 2021 China BioMed Innovation and Investment Conference (2021 CBIIC). The Forum consisted of three keynote speeches and one panel discussion.

Li Anmin, President of EagleHoldings Co., Ltd., was the moderator of the Forum.

Moderator:Li Anmin, President of EagleHoldings Co., Ltd.

Firstly,Yang Yanhua, Managing Partner of EverOne Group, shared his experience in domestic and overseas biomedical M&A under the topic “The Rapid Growth of the Pharmaceutical Industry and How We Transfer Risks”. Yang emphasized the importance of overall planning, including how to design appropriate trading framework and avoid political risk, legal risk and cultural risk.

Yang stressed that due diligence was very important in the process of M&A. The management risks and product risks of the target company could be exposed through detailed and rigorous due diligence, meanwhile, appropriate transaction terms could be designed to properly avoid these risks.

Yang Yanhua, Managing Partner of EverOne Group

Cynthia Wang, BD & Licensing Director of Les Laboratories Servier, shared the speech of “Global Transactions Case Sharing -- from MNC Perspective”. She introduced the history, corporate culture and innovative pharmaceutical investment and acquisition strategy. Its unique M&A style of European enterprise has let everyone feel new and fresh.

Cynthia Wang, BD & Licensing Director of Les Laboratories Servier

Leo L. Han, CEO of Quark Venture China/GDCC, presented a keynote speech entitled “Commercialization of Innovative Drug and Digital Therapy in China”. Quark Venture’s main investment is in the United States, focusing on areas include orthopedics, central nervous system, ophthalmology, oncology, artificial intelligence, cardiovascular and cerebrovascular. Quark Venture China hopes to apply its mature investment experience in Europe and America to China and develop more business opportunities together with Chinese investors.

Leo L. Han, CEO of Quark Venture China/GDCC

Wang Fei, CFO of 3SBio Inc. shared his company’s strategy of how to tap global innovation value based on clinical demand gap. Wang Fei showed many license-in and investment cases of 3SBio in the field of innovative drugs, and introduced the key cases in detail. The detailed data has shown 3SBio’s professional layout in innovative pharmaceutical.

Wang Fei, CFO of 3SBio Inc.

In the end, senior investment and acquisition professionals from Hillhouse Capital, Decheng Capital, Zai Lab, Kelun Biotech, Boan Biotechnology Co., Ltd. and other companies had a heated discussion on “Changes and Thoughts of the Investment Logic of Biotech”. All the panelists talked about the overall M&A of innovative pharmaceutical enterprises, environmental changes of license in/out, and personal understandings of this field with their own experiences. In addition, opinions on how to carry out innovative drug M&A and license were expressed under the current serious involution of the Chinese capital market.

Moderator: Dong Lyu, MD, Hillhouse Capital

Panelists: From left to right

Cherry Yi, Managing Director of GL Capital Group

Sammy Jiang, CEO of Shandong Boan Biotechnology Co., Ltd.

Tony Zhang, CEO of Tyligand Bioscience

Jonathan Wang, Executive Vice President of Business Development, Zai Lab

Xiangyang Tan, CSO of Biotherapeutics R&D Kelun Biopharmatheutical Co. Ltd.

Plenary Meeting

Plenary Meeting